• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物诱导的锥体外系症状量表(DIEPSS)塞尔维亚语版本:评定者间信度和重测信度。

Drug-induced Extrapyramidal Symptoms Scale (DIEPSS) Serbian Language version: Inter-rater and Test-retest Reliability.

机构信息

Institute of Mental Health, Palmoticeva 37, 11000, Belgrade, Serbia.

School of Medicine, University of Belgrade, Dr Subotica 8, 11000, Belgrade, Serbia.

出版信息

Sci Rep. 2017 Aug 14;7(1):8105. doi: 10.1038/s41598-017-08706-3.

DOI:10.1038/s41598-017-08706-3
PMID:28808283
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5556049/
Abstract

Drug-induced Extrapyramidal Symptoms Scale (DIEPSS) is developed in the era of second-generation antipsychotics and is suitable for evaluation of the low incidence of extrapyramidal symptoms occurring in the treatment of atypical antipsychotics, as well as the relationship between personal and social functioning. The study was carried out at the Institute of Mental Health in Serbia in 2015 Study used the 127 DIEPSS video clips material, recorded from 1987 till 2015. Four raters performed the assessment simultaneously, individually rating one assigned item immediately after seeing the video clip. For the purpose of evaluating test-retest reliability the second assessment of the same material was performed nine months after the first assessment. Inter-rater reliability was high for each individual item, with ICCs ranging from 0.769 to 0.949. The inter-rater reliability was highest for akathisia item and lowest for dyskinesia. The test-retest reliability was high for each individual item, with ICC ranging from 0.713 to 0.935. The test-retest reliability was highest for bradykinesia item and lowest for dystonia. The Serbian version of DIEPSS has high level of inter-rater and test-retest reliability. High values of concordance rates (ICC > 0.7) for each evaluated individual item suggest that items of DIEPSS are well defined.

摘要

药物引起的锥体外系症状量表(DIEPSS)是在第二代抗精神病药物时代开发的,适用于评估非典型抗精神病药物治疗中出现的锥体外系症状的低发生率,以及个人和社会功能之间的关系。该研究于 2015 年在塞尔维亚心理健康研究所进行,研究使用了 127 个 DIEPSS 视频片段材料,这些材料是从 1987 年到 2015 年记录的。四名评估者同时进行评估,在观看视频片段后立即单独评估一个指定的项目。为了评估测试-重测信度,在第一次评估后的九个月对相同的材料进行了第二次评估。每个单项的组内信度都很高,ICC 范围从 0.769 到 0.949。对于静坐不能项目,组内信度最高,对于运动障碍项目,组内信度最低。每个单项的测试-重测信度都很高,ICC 范围从 0.713 到 0.935。对于运动迟缓和运动障碍项目,测试-重测信度最低。DIEPSS 的塞尔维亚语版本具有很高的组内和重测信度。对于每个评估的单项,一致性率(ICC>0.7)的高值表明 DIEPSS 的项目定义良好。

相似文献

1
Drug-induced Extrapyramidal Symptoms Scale (DIEPSS) Serbian Language version: Inter-rater and Test-retest Reliability.药物诱导的锥体外系症状量表(DIEPSS)塞尔维亚语版本:评定者间信度和重测信度。
Sci Rep. 2017 Aug 14;7(1):8105. doi: 10.1038/s41598-017-08706-3.
2
Drug-Induced Extrapyramidal Symptoms Scale of the Norwegian version: inter-rater and test-retest reliability.挪威版药物所致锥体外系症状量表:评定者间信度和重测信度
Nord J Psychiatry. 2019 Nov;73(8):546-550. doi: 10.1080/08039488.2019.1665708. Epub 2019 Sep 18.
3
Slovenian Version of the Drug-Induced Extrapyramidal Symptoms Scale: Evaluation of Interrater and Test-Retest Reliability.斯洛文尼亚版药物诱导的锥体外系症状量表:评估评定者间和重测信度。
J Clin Psychopharmacol. 2023;43(4):361-364. doi: 10.1097/JCP.0000000000001682. Epub 2023 May 1.
4
Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders.药物性锥体外系症状量表(DIEPSS)的计量学特征:一种用于药物性运动障碍的实用综合评定量表。
Mov Disord. 2002 Nov;17(6):1354-9. doi: 10.1002/mds.10255.
5
The factor structure of extrapyramidal symptoms evaluated using the Drug-Induced Extrapyramidal Symptoms Scale in patients with schizophrenia: Results from the 2016 REAP AP-4 study.使用药物诱发的锥体外系症状量表评估精神分裂症患者的锥体外系症状的因子结构:来自 2016 年 REAP AP-4 研究的结果。
Hum Psychopharmacol. 2023 Mar;38(2):e2861. doi: 10.1002/hup.2861. Epub 2022 Dec 3.
6
[Translation and validation of a French version of the Young Mania Rating Scale (YMRS)].《青年躁狂评定量表(YMRS)法语版的翻译与验证》
Encephale. 2003 Nov-Dec;29(6):499-505.
7
Assessment of extrapyramidal symptoms during acute neuroleptic treatment.急性抗精神病药物治疗期间锥体外系症状的评估。
J Clin Psychiatry. 1995 Mar;56(3):94-100.
8
The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity.圣汉斯锥体外系综合征评定量表:信度与效度
Acta Psychiatr Scand. 1993 Apr;87(4):244-52. doi: 10.1111/j.1600-0447.1993.tb03366.x.
9
[Validating the Simpson-Angus Extrapyramidal Collateral Symptom Evaluation Scale].[验证辛普森-安格斯锥体外系副反应症状评定量表]
Rev Salud Publica (Bogota). 2006 Jan-Apr;8(1):74-87. doi: 10.1590/s0124-00642006000100007.
10
Manual for the Extrapyramidal Symptom Rating Scale (ESRS).锥体外系症状评定量表(ESRS)手册。
Schizophr Res. 2005 Jul 15;76(2-3):247-65. doi: 10.1016/j.schres.2005.02.013. Epub 2005 Apr 18.

引用本文的文献

1
Efficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial.鲁拉西酮与喹硫平缓释片治疗韩国急性精神分裂症精神病患者的疗效与安全性:一项随机、双盲、活性药物对照试验
Psychiatry Investig. 2024 Jul;21(7):762-771. doi: 10.30773/pi.2024.0052. Epub 2024 Jul 24.
2
Slovenian Version of the Drug-Induced Extrapyramidal Symptoms Scale: Evaluation of Interrater and Test-Retest Reliability.斯洛文尼亚版药物诱导的锥体外系症状量表:评估评定者间和重测信度。
J Clin Psychopharmacol. 2023;43(4):361-364. doi: 10.1097/JCP.0000000000001682. Epub 2023 May 1.
3
Oligoantigenic Diet Improves Children's ADHD Rating Scale Scores Reliably in Added Video-Rating.低抗原饮食在增加视频评分时能可靠地提高儿童多动症评定量表得分。
Front Psychiatry. 2020 Aug 20;11:730. doi: 10.3389/fpsyt.2020.00730. eCollection 2020.

本文引用的文献

1
Evaluation of the Expression Profile of Extrapyramidal Symptoms Due to Antipsychotics by Data Mining of Japanese Adverse Drug Event Report (JADER) Database.通过挖掘日本药品不良反应报告(JADER)数据库评估抗精神病药物所致锥体外系症状的表达谱。
Yakugaku Zasshi. 2017;137(1):111-120. doi: 10.1248/yakushi.16-00219.
2
The longitudinal trends in the relationship between drug-induced extrapyramidal symptoms and personal and social performance in a population of the patients with schizophrenia: A latent growth model.精神分裂症患者人群中药物引起的锥体外系症状与个人和社会功能表现之间的关系的纵向趋势:潜在增长模型。
Psychiatry Res. 2016 Apr 30;238:33-39. doi: 10.1016/j.psychres.2016.01.069. Epub 2016 Feb 2.
3
Rating scales to measure side effects of antipsychotic medication: A systematic review.用于衡量抗精神病药物副作用的评定量表:一项系统评价。
J Psychopharmacol. 2015 Aug;29(8):857-66. doi: 10.1177/0269881115593893. Epub 2015 Jul 8.
4
Quality of life in patients with schizophrenia: the impact of socio-economic factors and adverse effects of atypical antipsychotics drugs.精神分裂症患者的生活质量:社会经济因素的影响及非典型抗精神病药物的不良反应
Psychiatr Q. 2014 Sep;85(3):357-67. doi: 10.1007/s11126-014-9290-x.
5
SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects.SMARTS(与治疗相关的不良事件系统监测):开发实用的患者完成的清单,以评估抗精神病药物的副作用。
Ther Adv Psychopharmacol. 2014 Feb;4(1):15-21. doi: 10.1177/2045125313510195.
6
Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.抗精神病药物引起的运动障碍:CATIE 精神分裂症试验的启示。
Neurol Clin. 2011 Feb;29(1):127-48, viii. doi: 10.1016/j.ncl.2010.10.002.
7
Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons.第二代抗精神病药物与锥体外系副作用:头对头比较的系统评价和荟萃分析。
Schizophr Bull. 2012 Jan;38(1):167-77. doi: 10.1093/schbul/sbq042. Epub 2010 May 31.
8
Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research.药物性帕金森综合征评定量表的系统评价及对未来研究的建议。
J Clin Psychopharmacol. 2010 Feb;30(1):57-63. doi: 10.1097/JCP.0b013e3181c914b3.
9
Ethnic differences in the risks of adverse reactions to drugs used in the treatment of psychoses and depression: a systematic review and meta-analysis.治疗精神病和抑郁症所用药物不良反应风险的种族差异:系统评价与荟萃分析
Drug Saf. 2008;31(7):597-607. doi: 10.2165/00002018-200831070-00005.
10
Side effects of atypical antipsychotics: a brief overview.非典型抗精神病药物的副作用:简要概述。
World Psychiatry. 2008 Feb;7(1):58-62. doi: 10.1002/j.2051-5545.2008.tb00154.x.